Abbvie pulls plug on Swedish R&D partnership

Swedish biotech firm Bioarctic expresses its disappointment over Abbvie’s decision to terminate a collaborative partnership on potential Parkinson’s treatments.
Photo: Abbvie / PR
Photo: Abbvie / PR
by andreas lønstrup, translated by daniel pedersen

US-based Abbvie has decided to end a collaboration with Swedish biotech firm Bioartic on the latter’s portfolio of alpha-synuclein antibodies, the company has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading